Sartorius Stedim Biotech S.A./ADR
No SEC Form 4 filings for $SDMHF in the last 30 days.
See all $SDMHF insider activity →Sartorius Stedim Biotech SA reported 9M 2026 sales of €2.289B, a 6.5% increase, with an EBITDA margin of 31.3% and net profit of €277M. Free cash flow rose to €264M, and the company maintained its full-year guidance, refining its capex ratio to ~13%.
Goldman Sachs assigned a Buy rating to Sartorius Stedim Biotech, following a similar rating from Barclays. The rating is based on a weighted average of various metrics, including valuation and EPS revisions. The company's stock is currently trading at 212.00 EUR on Euronext Paris.
UBS upgraded Sartorius Stedim Biotech from Neutral to Buy, citing a weighted average of ratings including valuation, EPS revisions, and visibility. The company's stock is currently at 192.20 EUR, up 5.08% over 5 days and 6.13% year-to-date.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning SDMHF (Sartorius Stedim Biotech S.A./ADR). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent SDMHF coverage spans earnings, financial news and market movers.
Sartorius Stedim Biotech SA reported 9M 2026 sales of €2.289B, a 6.5% increase, with an EBITDA margin of 31.3% and net profit of €277M. Free cash flow rose to €264M, and the company maintained its full-year guidance, refining its capex ratio to ~13%.
Goldman Sachs assigned a Buy rating to Sartorius Stedim Biotech, following a similar rating from Barclays. The rating is based on a weighted average of various metrics, including valuation and EPS revisions. The company's stock is currently trading at 212.00 EUR on Euronext Paris.
UBS upgraded Sartorius Stedim Biotech from Neutral to Buy, citing a weighted average of ratings including valuation, EPS revisions, and visibility. The company's stock is currently at 192.20 EUR, up 5.08% over 5 days and 6.13% year-to-date.
Sartorius Stedim Biotech (STDM) stock rose 5.0% to €192.1 after UBS upgraded its rating to Buy and raised its price target to €260 from €220. UBS cited strong demand for bioprocess consumables and anticipated biosimilar launches. The upgrade also boosted parent company Sartorius AG. The move was driven by company-specific news, not broader market trends.
UBS upgraded Sartorius Stedim Biotech to buy, raising its price target to €260 from €220. JP Morgan upgraded Michelin to overweight, increasing its target to €42 from €35. JP Morgan also trimmed Elis's target to €28.20, while UBS raised Getlink's to €19.80.
AlphAI scores every news story that mentions SDMHF with an AI model for sentiment and relevance, and aggregates insider trades from Sartorius Stedim Biotech S.A./ADR's SEC EDGAR Form 4 filings. Figures refresh continuously.
Sartorius Stedim Biotech SA reported 9M 2026 sales of €2.289B, a 6.5% increase, with an EBITDA margin of 31.3% and net profit of €277M. Free cash flow rose to €264M, and the company maintained its full-year guidance, refining its capex ratio to ~13%.
1 min readGoldman Sachs assigned a Buy rating to Sartorius Stedim Biotech, following a similar rating from Barclays. The rating is based on a weighted average of various metrics, including valuation and EPS revisions. The company's stock is currently trading at 212.00 EUR on Euronext Paris.
1 min readUBS upgraded Sartorius Stedim Biotech from Neutral to Buy, citing a weighted average of ratings including valuation, EPS revisions, and visibility. The company's stock is currently at 192.20 EUR, up 5.08% over 5 days and 6.13% year-to-date.
1 min readSartorius Stedim Biotech (STDM) stock rose 5.0% to €192.1 after UBS upgraded its rating to Buy and raised its price target to €260 from €220. UBS cited strong demand for bioprocess consumables and anticipated biosimilar launches. The upgrade also boosted parent company Sartorius AG. The move was driven by company-specific news, not broader market trends.
2 min readUBS upgraded Sartorius Stedim Biotech to buy, raising its price target to €260 from €220. JP Morgan upgraded Michelin to overweight, increasing its target to €42 from €35. JP Morgan also trimmed Elis's target to €28.20, while UBS raised Getlink's to €19.80.
1 min readSartorius Stedim Biotech reported 1H 2026 sales revenue of EUR 1,527m, up 6.4% in constant currencies including U.S. tariff refunds and customer surcharge compensation. Underlying EBITDA was EUR 479m (31.4% margin) and net profit EUR 181m. Management confirmed 2026 guidance for sales growth of 6% to 10% in constant currencies and EBITDA margin slightly above 31%.
4 min read
